|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS60192263A
(ja)
|
1984-03-13 |
1985-09-30 |
Teijin Ltd |
免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
CA1276103C
(en)
|
1984-10-02 |
1990-11-13 |
Fumiaki Taguchi |
Substance-conjugated complement component c1q
|
|
JPS61271455A
(ja)
|
1985-05-28 |
1986-12-01 |
Olympus Optical Co Ltd |
免疫学的分析方法
|
|
EP0226660B1
(de)
|
1985-12-24 |
1989-07-12 |
O & K Orenstein & Koppel Aktiengesellschaft |
Schaufelradschneidvorrichtung
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4866132A
(en)
|
1986-04-17 |
1989-09-12 |
The Research Foundation Of State University Of New York |
Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5256334A
(en)
|
1988-09-08 |
1993-10-26 |
The Research Foundation Of The State University Of New York |
Homogeneous radiopaque polymer-organobismuth composites
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
US5346981A
(en)
|
1993-01-13 |
1994-09-13 |
Miles Inc. |
Radiopaque polyurethanes
|
|
CA2115811A1
(en)
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
PT716611E
(pt)
|
1993-09-01 |
2002-06-28 |
Sanquin Bloedvoorziening |
Metodo para reduzir a lesao do miocardio durante um enfarte do miocardio agudo
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5625048A
(en)
|
1994-11-10 |
1997-04-29 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
KR100551104B1
(ko)
|
1994-12-09 |
2006-02-09 |
임페리얼 컬리지 이노베이션스 리미티드 |
유전자의 동정
|
|
WO1996019487A1
(en)
|
1994-12-22 |
1996-06-27 |
Nissan Chemical Industries, Ltd. |
Organobismuth derivatives and process for producing the same
|
|
US5958713A
(en)
|
1995-01-31 |
1999-09-28 |
Novo Nordisk A/S |
Method of detecting biologically active substances by using green fluorescent protein
|
|
US5670477A
(en)
|
1995-04-20 |
1997-09-23 |
Joseph F. Poduslo |
Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
|
|
US5968738A
(en)
|
1995-12-06 |
1999-10-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
|
|
US6020192A
(en)
|
1996-01-18 |
2000-02-01 |
University Of Florida |
Humanized green fluorescent protein genes and methods
|
|
US5874304A
(en)
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
ES2166097T5
(es)
|
1996-08-27 |
2007-03-16 |
Novartis Vaccines And Diagnostics, Inc. |
Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
|
|
US5976796A
(en)
|
1996-10-04 |
1999-11-02 |
Loma Linda University |
Construction and expression of renilla luciferase and green fluorescent protein fusion genes
|
|
TW371617B
(en)
|
1996-10-09 |
1999-10-11 |
Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau |
Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
|
|
US6969601B2
(en)
|
1997-04-03 |
2005-11-29 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
KR20010015856A
(ko)
|
1997-12-12 |
2001-02-26 |
마크로메드 인코퍼레이션 |
단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
|
|
JP4437192B2
(ja)
|
1998-02-20 |
2010-03-24 |
タノックス インコーポレイテッド |
補体活性化阻害剤
|
|
US5985577A
(en)
|
1998-10-14 |
1999-11-16 |
The Trustees Of Columbia University In The City Of New York |
Protein conjugates containing multimers of green fluorescent protein
|
|
US6492403B1
(en)
|
1999-02-09 |
2002-12-10 |
3-Dimensional Pharmaceuticals, Inc. |
Methods of treating C1s-mediated diseases and conditions and compositions thereof
|
|
AU4369000A
(en)
|
1999-04-26 |
2000-11-10 |
Duke University |
Inhibition of complement action
|
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
|
EP1250594A4
(en)
|
2000-01-19 |
2003-05-07 |
Biotransplant Inc |
PORC UNABLE TO TRANSMIT PORCINE ENDOGENEOUS RETROVIRUS, AND USES THEREOF
|
|
CA2398707C
(en)
|
2000-01-31 |
2010-10-26 |
Pharming Intellectual Property B.V. |
C1 inhibitor produced in the milk of transgenic mammals
|
|
US6998468B2
(en)
|
2000-03-23 |
2006-02-14 |
Tanox, Inc. |
Anti-C2/C2a inhibitors of complement activation
|
|
EP1349874A2
(en)
*
|
2000-06-21 |
2003-10-08 |
ZymoGenetics, Inc. |
Peptide and polypeptide inhibitors of complement c1s
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
GB0105924D0
(en)
|
2001-03-09 |
2001-04-25 |
Microscience Ltd |
Promoter
|
|
GB0117326D0
(en)
|
2001-07-16 |
2001-09-05 |
Univ Aberdeen |
Napthoquinone-type inhibitors of protein aggregation
|
|
WO2003009803A2
(en)
|
2001-07-26 |
2003-02-06 |
Alexion Pharmaceuticals Inc. |
Method of improving cognitive function
|
|
IL160701A0
(en)
|
2001-09-21 |
2004-08-31 |
Mitsubishi Pharma Corp |
3-substituted-4-pyrimidone derivatives
|
|
EP1463802A1
(en)
|
2002-01-11 |
2004-10-06 |
GTC Biotherapeutics, Inc. |
Method and system for fusion and activation following nuclear transfer in reconstructed embryos
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
SE0202880D0
(sv)
|
2002-07-26 |
2002-09-30 |
Wieslab Ab |
Complement system deficiency assay
|
|
US7666627B2
(en)
|
2002-08-08 |
2010-02-23 |
Targetex Kft. |
Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
JP4601426B2
(ja)
|
2002-09-06 |
2010-12-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体成分ｃ５に対する抗体を使用する喘息の処置の方法
|
|
US7361339B2
(en)
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
|
EP2266606B1
(en)
*
|
2003-05-15 |
2014-09-10 |
Genentech, Inc. |
Methods and compositions for the prevention and treatment of sepsis
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US7923010B2
(en)
|
2003-09-11 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US8501705B2
(en)
|
2003-09-11 |
2013-08-06 |
The Board Of Regents Of The University Of Texas System |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
|
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
AU2004297616B2
(en)
|
2003-12-04 |
2008-12-18 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8840893B2
(en)
*
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US20060018896A1
(en)
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
|
ES2631127T3
(es)
|
2004-06-10 |
2017-08-28 |
Omeros Corporation |
Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
|
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2005313971B2
(en)
|
2004-12-08 |
2011-10-13 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
|
US20090016959A1
(en)
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
|
KR20080002832A
(ko)
*
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
CA2654440C
(en)
|
2005-06-06 |
2013-09-03 |
Girish J. Kotwal |
Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
|
|
EP1937720B1
(en)
*
|
2005-08-18 |
2014-04-09 |
Ramot at Tel-Aviv University Ltd. |
Single chain antibodies against beta-amyloid peptide
|
|
US8741260B2
(en)
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
JP5219819B2
(ja)
|
2005-10-21 |
2013-06-26 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
補体活性化を阻害する修飾プロテアーゼ
|
|
WO2007070375A2
(en)
|
2005-12-09 |
2007-06-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
US9480658B2
(en)
|
2005-12-09 |
2016-11-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptic maintenance
|
|
PL2380587T3
(pl)
|
2005-12-21 |
2018-03-30 |
Pharming Intellectual Property B.V. |
Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
|
|
FR2897868B1
(fr)
|
2006-02-24 |
2012-08-31 |
Lab Francais Du Fractionnement |
Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
|
|
NZ571791A
(en)
|
2006-03-08 |
2012-03-30 |
Archemix Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
NZ615012A
(en)
*
|
2006-03-21 |
2015-11-27 |
Genentech Inc |
Combinatorial therapy involving alpha5beta1 antagonists
|
|
US9388235B2
(en)
|
2006-09-05 |
2016-07-12 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
EP2073898A1
(en)
|
2006-10-10 |
2009-07-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Complement inhibition for improved nerve regeneration
|
|
US7858752B2
(en)
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
|
CN101679219B
(zh)
|
2006-12-19 |
2014-08-13 |
港大科桥有限公司 |
合成离子通道
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
US8192742B2
(en)
*
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
PE20090943A1
(es)
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
US8236307B2
(en)
|
2007-08-03 |
2012-08-07 |
Genentech, Inc. |
Humanized anti-FGF19 antagonists and methods using same
|
|
HRP20150279T1
(hr)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
CA2720682A1
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
US20110081347A1
(en)
|
2008-06-04 |
2011-04-07 |
Macrogenics, Inc. |
Antibodies with Altered Binding to FcRn and Methods of Using Same
|
|
WO2009151634A1
(en)
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
US20110311550A1
(en)
*
|
2008-10-24 |
2011-12-22 |
The Scripps Research Institute |
Agents for hcv treatment
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
CA2740192C
(en)
*
|
2008-12-01 |
2019-12-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for detection of complement fixing antibodies
|
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
CN102348723A
(zh)
|
2008-12-05 |
2012-02-08 |
安吉奥开米公司 |
肽治疗剂轭合物及其应用
|
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
CA2766565A1
(en)
*
|
2009-06-23 |
2010-12-29 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
DK2488203T3
(en)
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
WO2011102342A1
(ja)
|
2010-02-16 |
2011-08-25 |
国立大学法人京都工芸繊維大学 |
抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
|
|
ES2615732T3
(es)
|
2010-03-01 |
2017-06-08 |
Alexion Pharmaceuticals, Inc. |
Composiciones para tratar la enfermedad de Degos
|
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
|
CA2799746C
(en)
|
2010-05-17 |
2020-11-24 |
Sai Reddy |
Rapid isolation of monoclonal antibodies from animals
|
|
WO2011163394A2
(en)
|
2010-06-22 |
2011-12-29 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
SG186397A1
(en)
|
2010-06-22 |
2013-01-30 |
Univ Colorado Regents |
Antibodies to the c3d fragment of complement component 3
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
US8865164B2
(en)
|
2010-11-02 |
2014-10-21 |
Kypha, Inc. |
Detecting complement activation
|
|
EP2648752B1
(en)
|
2010-12-06 |
2017-02-15 |
Seattle Genetics, Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
|
BR112013025917A2
(pt)
|
2011-04-08 |
2016-12-20 |
Omeros Corp |
uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
|
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
JP6127063B2
(ja)
|
2011-12-22 |
2017-05-10 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
|
|
JP6081699B2
(ja)
|
2011-12-28 |
2017-02-15 |
雅史 溝上 |
Ｉｌ−２８ｂの分析方法
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
EP3722320A3
(en)
|
2012-10-25 |
2020-12-30 |
Bioverativ USA Inc. |
Anti-complement c1s antibodies and uses thereof
|
|
DK2914291T3
(da)
|
2012-11-02 |
2022-05-16 |
Bioverativ Usa Inc |
Anti-komplement-c1s-antistoffer og anvendelser deraf
|
|
WO2014119969A1
(ko)
|
2013-01-31 |
2014-08-07 |
서울대학교 산학협력단 |
보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
EP2997045A4
(en)
|
2013-05-15 |
2016-11-23 |
Annexon Inc |
ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
|
|
ES2904709T3
(es)
|
2013-05-23 |
2022-04-05 |
Broteio Pharma B V |
Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas
|
|
DK3019240T3
(da)
|
2013-07-09 |
2024-06-03 |
Annexon Inc |
Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
|
|
WO2015084999A1
(en)
|
2013-12-06 |
2015-06-11 |
True North Therapeutics, Inc. |
Complement component biomarker assays
|
|
CN107073113A
(zh)
|
2014-10-18 |
2017-08-18 |
辉瑞大药厂 |
抗il‑7r抗体组合物
|
|
CA2981321A1
(en)
|
2015-04-06 |
2016-10-13 |
True North Therapeutics, Inc. |
Humanized anti-c1s antibodies and methods of use thereof
|
|
MX2017016835A
(es)
|
2015-06-26 |
2018-08-01 |
Bioverativ Usa Inc |
Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
|
|
CN110300520B
(zh)
|
2016-10-12 |
2022-10-04 |
美国比奥维拉迪维股份有限公司 |
抗C1s抗体及其使用方法
|
|
CR20190468A
(es)
|
2017-03-14 |
2019-12-17 |
Bioverativ Usa Inc |
Métodos para tratar enfermedades y trastornos mediados por completo
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
EP3774892A4
(en)
|
2018-04-13 |
2022-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
IL300376A
(en)
|
2020-08-06 |
2023-04-01 |
Bioverativ Usa Inc |
Inflammatory cytokines and fatigue in subjects with complement-mediated disease
|
|
WO2022212645A1
(en)
|
2021-03-31 |
2022-10-06 |
Bioverativ Usa Inc. |
Reducing surgery-associated hemolysis in cold agglutinin disease patients
|
|
CA3260415A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES
|